Alkermes plc Cash Flow Conversion Efficiency
Alkermes plc cash flow conversion efficiency. Based on the latest financial reports, Alkermes plc (8AK) has a cash flow conversion efficiency ratio of -0.095x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-165.74 Million ≈ $-193.77 Million USD) by net assets (€1.75 Billion ≈ $2.05 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alkermes plc market cap and net worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Alkermes plc (2013–2025)
Cash flow conversion efficiency of Alkermes plc from 2013 to 2025. This chart illustrates how Alkermes plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Alkermes plc stock quote for real-time trading data and today's change.
Alkermes plc Cash Flow Conversion Ratio Explained
Alkermes plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alkermes plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alkermes plc ranked by their cash flow conversion efficiency. Review Alkermes plc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unicaja Banco SA
MC:UNI
|
0.006x |
|
Lottomatica Group SpA
NYSE:LOTMY
|
0.362x |
|
Schaeffler AG
XETRA:SHA0
|
0.042x |
|
Sonic Healthcare Ltd
AU:SHL
|
0.085x |
|
Fluor Corporation
NYSE:FLR
|
0.039x |
|
Huadong Medicine Co Ltd
SHE:000963
|
0.006x |
|
Korea Aerospace Industries
KO:047810
|
-0.073x |
|
Henan Shijia Photons Technology Co Ltd
SHG:688313
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Alkermes plc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Alkermes plc from 2013 to 2025. Also see 8AK asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.82 Billion ≈ $2.13 Billion |
€520.75 Million ≈ $608.82 Million |
0.286x | -4.51% |
| 2024-12-31 | €1.46 Billion ≈ $1.71 Billion |
€439.12 Million ≈ $513.38 Million |
0.300x | -10.18% |
| 2023-12-31 | €1.20 Billion ≈ $1.41 Billion |
€401.35 Million ≈ $469.22 Million |
0.334x | +1555.17% |
| 2022-12-31 | €1.04 Billion ≈ $1.22 Billion |
€21.04 Million ≈ $24.60 Million |
0.020x | -77.95% |
| 2021-12-31 | €1.11 Billion ≈ $1.30 Billion |
€101.72 Million ≈ $118.92 Million |
0.091x | +7.86% |
| 2018-12-31 | €1.17 Billion ≈ $1.37 Billion |
€99.28 Million ≈ $116.07 Million |
0.085x | +431.28% |
| 2017-12-31 | €1.20 Billion ≈ $1.41 Billion |
€19.19 Million ≈ $22.44 Million |
0.016x | +130.24% |
| 2016-12-31 | €1.21 Billion ≈ $1.41 Billion |
€-63.80 Million ≈ $-74.59 Million |
-0.053x | -71.78% |
| 2015-12-31 | €1.31 Billion ≈ $1.54 Billion |
€-40.36 Million ≈ $-47.19 Million |
-0.031x | -485.09% |
| 2014-12-31 | €1.40 Billion ≈ $1.63 Billion |
€11.14 Million ≈ $13.02 Million |
0.008x | -94.24% |
| 2013-12-31 | €1.07 Billion ≈ $1.25 Billion |
€147.53 Million ≈ $172.47 Million |
0.138x | -- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more